my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
01-10-2012: Oncodesign and Ipsen announced that the two companies have entered into a research collaboration to discover and develop LRRK2 kinase inhibitors as potential therapeutic agents against Parkinson's Disease and for potential additional uses in other therapeutic areas. Oncodesign and Ipsen will leverage their respective expertise to bring innovative therapeutic solutions to Parkinson patients.
Oncodesign’s Nanocyclix(R) is a proprietary medicinal chemistry technology based on a macrocyclisation process of small chemical molecules that gives access to potent and highly selective small molecule kinase inhibitors with attractive physicochemical and ADME properties. Oncodesign has identified Nanocyclix(R) leads against a broad range of known and unexplored kinases (notably the LRRK2 program) with potential in multiple therapeutic areas. Ipsen will apply its expertise in pharmaceutical R&D and translational sciences while leveraging its network of academic and medical leaders in neurosciences.
Under the terms of the agreement, Ipsen is granted two exclusive options to exclusively license Oncodesign's LRRK2 inhibitor program, notably upon successfully reaching clinical proof of concept, with worldwide development, manufacturing and commercialization rights. Oncodesign is entitled to a technology access fee, funding of the program's research and early development activities, and upon exercise of the license options, opt-in fees and additional development, regulatory and commercial milestone payments potentially totaling EUR115 million (approx. USD149 million) for the development of molecules in two or more indications, and tiered royalties on net sales.
Contact / Request information
Request further information free of charge:
Watchlist
This is where you can add this news to your personal favourites
Oncodesign and Ipsen announced that the two companies have entered into a research collaboration to discover and develop LRRK2 kinase inhibitors as potential therapeutic agents against Parkinson's Disease and for potential additional uses in other therapeutic areas. Oncodesign and Ipsen wil ... more
Oncodesign to Develop Experimental Cancer Models for sanofi-aventis
Oncodesign has signed a two-year service contract with sanofi-aventis under which it is to supply and develop exclusive, experimental models in different types of cancer for sanofi-aventis. Unlike traditional models, which are derived from cultured cell lines, the models that Oncodesign is ... more
Oncodesign announces EUR 10 million funding for oncology biomarker program IMAkinib
Oncodesign announced that French innovation agency, OSEO, will provide more than 40 percent of the funding for the IMAkinib program, aimed at oncology biomarker development. The total cost of the program will be around EUR 24.7 million over eight years. Oncodesign heads the project in colla ... more
Our mission is to discover and develop effective therapies against cancer. To reach this aim, we identify and validate molecular targets involved in cancer pathologies. Our ambition is to become the world leader in the area of the preclinical evaluation of novel anticancer therapeutics. W ... more
Oncodesign and Ipsen announced that the two companies have entered into a research collaboration to discover and develop LRRK2 kinase inhibitors as potential therapeutic agents against Parkinson's Disease and for potential additional uses in other therapeutic areas. Oncodesign and Ipsen wil ... more
Santhera Pharmaceuticals and Ipsen announced a license agreement for the development and commercialization of fipamezole (antagonist of the adrenergic alpha-2 receptor) for territories outside of North America and Japan. This first-in-class compound is currently under investigation for the ... more
Ipsen and PHARNEXT conclude an exclusive research, development and marketing agreement
Ipsen and Pharnext SAS, a biopharmaceutical company specializing in the development of innovative treatments, today announced they have entered into an exclusive research, development and marketing agreement regarding innovative drug candidates intended for the treatment of Charcot Marie-T ... more
About CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2012 CHEMIE.DE Information Service GmbH, All rights reserved
